Kyorin Pharmaceutical
Kyorin Pharmaceutical Co., Ltd., commonly referred to as Kyorin, is a prominent player in the pharmaceutical industry, headquartered in Tokyo, Japan. Established in 1923, the company has made significant strides in research and development, particularly in the fields of respiratory and infectious diseases, as well as urology. Kyorin is renowned for its innovative products, including prescription medications and over-the-counter solutions, which are distinguished by their efficacy and safety profiles. The company has achieved notable market presence, particularly in Japan and other key regions across Asia. With a commitment to advancing healthcare, Kyorin continues to focus on developing unique therapies that address unmet medical needs, solidifying its position as a trusted name in the pharmaceutical sector.
DitchCarbon Score
How does Kyorin Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kyorin Pharmaceutical's score of 23 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Kyorin Pharmaceutical's reported carbon emissions
In 2023, Kyorin Pharmaceutical reported total carbon emissions of approximately 41,812,000 kg CO2e. This figure includes 12,895,000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources. Scope 2 emissions, related to the generation of purchased electricity, steam, heating, and cooling, accounted for about 12,110,000 kg CO2e. Additionally, Scope 3 emissions, which cover indirect emissions from the value chain, totalled approximately 16,807,000 kg CO2e. Notable contributors to Scope 3 emissions include capital goods (5,263,000 kg CO2e), purchased goods and services (6,233,000 kg CO2e), and employee commuting (977,000 kg CO2e). Despite the significant emissions reported, Kyorin Pharmaceutical has not disclosed specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of documented reduction strategies suggests a need for enhanced climate commitments within the pharmaceutical industry context. As the sector increasingly prioritises sustainability, Kyorin's future climate actions will be crucial in aligning with global efforts to mitigate climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2023 | |
|---|---|
| Scope 1 | 12,895,000 |
| Scope 2 | 12,110,000 |
| Scope 3 | 16,807,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Kyorin Pharmaceutical is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
